LP
KYMR icon

LMR Partners’s Kymera Therapeutics KYMR Stock Holding History

LMR Partners’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-121,400
Closed -$9.45M – 1691
2025
Q4 		$9.45M Buy
+121,400
New +$8.2M 0.02% 404

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

LMR Partners's KYMR Position: Q4 2021 in Review

LMR Partners sold out of Kymera Therapeutics (KYMR) in Q4 2021, closing a stake of 65,941 shares — an estimated $3.87M sold.

LMR Partners first reported a position in KYMR in Q2 2021 and held it in 2 quarters. The position peaked at $3.87M in Q3 2021. 128 funds tracked by Wall St. Rank hold KYMR as of Q4 2021.

  • LMR Partners reported no remaining Kymera Therapeutics position as of Q4 2021 after selling out during the quarter.
  • LMR Partners sold 65,941 Kymera Therapeutics shares in Q4 2021, an estimated $3.87M.
  • LMR Partners first reported a position in Kymera Therapeutics in Q2 2021 and held it in 2 quarters.
  • LMR Partners's Kymera Therapeutics position peaked at $3.87M in Q3 2021.
  • 128 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q4 2021.

Based on LMR Partners's 13F filing for Q4 2021, filed 14 Feb 2022.